The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report

BACKGROUND: Since tacrolimus ointment was approved by the U.S. Food and Drug Administration (FDA) as a promising treatment for atopic dermatitis, it has been approved in more than 30 additional countries, including numerous European Union member nations. Moreover, in the current clinical routine the...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Jürgen C, Houben, Roland, Vetter, Claudia S, Bröcker, Eva B
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1386691/
https://www.ncbi.nlm.nih.gov/pubmed/16405733
http://dx.doi.org/10.1186/1471-2407-6-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1386691/
https://www.ncbi.nlm.nih.gov/pubmed/16405733
http://dx.doi.org/10.1186/1471-2407-6-7

Ejemplares similares